恶性胶质瘤的分子靶向治疗  

Molecular targeted therapy in glioblastoma

作　　者：南阳[1] 钟跃[1] 

机构地区：[1]天津医科大学总医院神经外科,300052

出　　处：《国际肿瘤学杂志》2017年第9期689-692,共4页Journal of International Oncology

基　　金：国家自然科学基金（81572490）

摘　　要：恶性胶质瘤是颅内最常见的恶性脑肿瘤，预后极差。随着肿瘤分子生物学的发展，针对恶性胶质瘤的分子靶向治疗已成为其综合治疗不可或缺的一部分。恶性胶质瘤靶向治疗药物不断涌现，包括酪氨酸激酶抑制剂、组蛋白去乙酰化酶抑制剂、磷脂酰肌醇3-激酶抑制剂、缺氧诱导因子-1α抑制剂、钠-钾泵抑制剂等。随着新型分子靶向治疗的不断发展，可能会发现更有效的恶性胶质瘤分子靶向治疗疗法，为恶性胶质瘤的个体化治疗开辟新的途径。Glioblastomas is the most common malignant primary brain tumors and the prognosis is very poor. With the development of tumor molecular biology, molecular targeted therapy for glioblastomas has become an integral part of its comprehensive treatment. Targeted therapy drugs of glioblastomas are emerging, including tyrosine kinase inhibitors, histone deacetylase inhibitors, phosphatidylinositol 3-kinase inhibitors, hypoxia inducible factor-lot inhibitors, sodium-potassium pump inhibitors, et al. With the development of new molecular targeted therapy, more effective or even treatment measures of glioblastomas might be found, which can provide a new approach for the individualized treatment of glioblastomas.

关 键 词：神经胶质瘤 靶向治疗 

分 类 号：R739.4[医药卫生—肿瘤]